Applied Genetic Technologies Corp. (NASDAQ:AGTC) shares shot up 3.7% during trading on Tuesday . The company traded as high as $15.89 and last traded at $15.76, with a volume of 104,504 shares. The stock had previously closed at $15.20.

A number of research firms recently commented on AGTC. Cantor Fitzgerald reissued a “buy” rating and issued a $32.00 price target on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. Zacks Investment Research cut Applied Genetic Technologies Corp. from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Wells Fargo & Co. reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. Finally, Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a report on Monday, April 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $26.00.

The firm’s 50-day moving average is $15.12 and its 200-day moving average is $15.07. The company’s market cap is $272.30 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last posted its earnings results on Monday, May 9th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.05 by $0.06. During the same period last year, the business earned ($0.38) earnings per share. The company had revenue of $12 million for the quarter, compared to analyst estimates of $12.98 million. The firm’s revenue was up 4125.4% on a year-over-year basis. On average, analysts forecast that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current year.

An institutional investor recently bought a new position in Applied Genetic Technologies Corp. stock. Globeflex Capital L P bought a new stake in Applied Genetic Technologies Corp. (NASDAQ:AGTC) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,300 shares of the company’s stock, valued at approximately $1,189,000. Globeflex Capital L P owned 0.32% of Applied Genetic Technologies Corp. as of its most recent SEC filing.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.